Relation’s 'Lab-in-the-Loop' platform combines human genetics, single-cell multi-omics directly from human tissue, functional assays, and machine learning to discover novel disease interventions.

The company has programmes across metabolic and immune diseases. As of Q4 2024, the company has raised over $80 million from leading investors.